# CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma

> **NCT04387071** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Southern California** · enrollment: 2 (actual)

## Conditions studied

- Locally Advanced Malignant Solid Neoplasm
- Metastatic Pancreatic Adenocarcinoma
- Stage IV Pancreatic Cancer AJCC v8
- Unresectable Malignant Solid Neoplasm

## Interventions

- **BIOLOGICAL:** Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949
- **DRUG:** VLP-encapsulated TLR9 Agonist CMP-001

## Key facts

- **NCT ID:** NCT04387071
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-29
- **Primary completion:** 2022-12-28
- **Final completion:** 2022-12-28
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Study drug no longer available
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04387071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04387071, "CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04387071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*